Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

February 17, 2023

Study Completion Date

February 17, 2023

Conditions

ABBV-154

Interventions

DRUG

ABBV-154 Dose Formulation A

Subcutaneous Injection

DRUG

ABBV-154 Dose Formulation B

Subcutaneous Injection

Trial Locations (2)

Acpru /Id# 250429, Grayslake

PPD Clinical Research Unit -Las Vegas /ID# 250650, Las Vegas